Literature DB >> 15522466

The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart.

Małgorzata Bartnik1, Lars Rydén, Roberto Ferrari, Klas Malmberg, Kalevi Pyörälä, Maarten Simoons, Eberhard Standl, Jordi Soler-Soler, John Ohrvik.   

Abstract

AIM: The objective behind the Euro Heart Survey on diabetes and the heart was to study the prevalence of abnormal glucose regulation in adult patients with coronary artery disease (CAD). METHODS AND
RESULTS: The survey engaged 110 centres in 25 countries recruiting 4196 patients referred to a cardiologist due to CAD out of whom 2107 were admitted on an acute basis and 2854 had an elective consultation. Patient data were collected via a web-based case record form. An oral glucose tolerance test (OGTT) was used for the characterisation of the glucose metabolism. Thirty-one per cent of the patients had diabetes. An OGTT was performed on the 1920 patients without known diabetes, of whom 923 had acute and 997 had a stable manifestation of CAD, respectively. In patients with acute CAD, 36% had impaired glucose regulation and 22% newly detected diabetes. In the stable group these proportions were 37% and 14%.
CONCLUSION: This survey demonstrates that normal glucose regulation is less common than abnormal glucose regulation in patients with CAD. OGTT easily discloses the glucometabolic state and should be a routine procedure. The knowledge of glucometabolic state among these patients should influence their future management because it has great potential to improve the outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15522466     DOI: 10.1016/j.ehj.2004.07.027

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  128 in total

1.  Oral glucose tolerance test in patients with undiagnosed diabetes and coronary artery disease: when should it be performed?

Authors:  A Kollias; E Diamanti-Kandarakis
Journal:  Diabetologia       Date:  2012-02-04       Impact factor: 10.122

2.  4th Annual Symposium on Self Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 12-14, 2011, Budapest, Hungary.

Authors:  Boris N Mankovsky
Journal:  Diabetes Technol Ther       Date:  2011-10-04       Impact factor: 6.118

3.  Implementation of Cardiovascular Disease Prevention Guidelines in Clinical Practice-Can We Do Better?

Authors:  Kornelia Kotseva
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-12

Review 4.  Prediabetes and cardiovascular risk in hypertensive patients.

Authors:  Julian Segura; Cecilia Roldán; Jose A García-Donaire; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

5.  Mortality after myocardial infarction in patients with diabetes mellitus.

Authors:  Akhil Kapur; Rodney De Palma
Journal:  Heart       Date:  2007-12       Impact factor: 5.994

Review 6.  Stress hyperglycaemia.

Authors:  Kathleen M Dungan; Susan S Braithwaite; Jean-Charles Preiser
Journal:  Lancet       Date:  2009-05-23       Impact factor: 79.321

7.  Recognition of incident diabetes mellitus during an acute myocardial infarction.

Authors:  Suzanne V Arnold; Joshua M Stolker; Kasia J Lipska; Philip G Jones; John A Spertus; Darren K McGuire; Silvio E Inzucchi; Abhinav Goyal; Thomas M Maddox; Marcus Lind; Divya Gumber; Supriya Shore; Mikhail Kosiborod
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-04-21

8.  The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention.

Authors:  Kornelia Kotseva
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 9.  Clinical significance of glycated hemoglobin in the acute phase of ST elevation myocardial infarction.

Authors:  Chiara Lazzeri; Serafina Valente; Marco Chiostri; Maria Grazia D'Alfonso; Gian Franco Gensini
Journal:  World J Cardiol       Date:  2014-04-26

Review 10.  [Care of patients after coronary stent implantation: what is important in practice?].

Authors:  V Schächinger
Journal:  Internist (Berl)       Date:  2007-12       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.